Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience (pages 527–535)
Esther Diana Rossi, Maurizio Martini, Sara Capodimonti, Tonia Cenci, Patrizia Straccia, Basilio Angrisani, Costantino Ricci, Paola Lanza, Celestino Pio Lombardi, Alfredo Pontecorvi, Luigi Maria Larocca and Guido Fadda
Article first published online: 17 MAR 2014 | DOI: 10.1002/cncy.21416
BRAF mutation is a strong indicator of papillary thyroid cancer because of its high specificity and positive predictive value, and it can easily be evaluated on thyroid cytologic samples. The new VE1 immunomarker—a monoclonal antibody directed against the mutated BRAF V600E protein—may be a valid alternative to DNA-based methods and produces good results in the presence of moderate and/or strong expression.